Last updated: March 5, 2026
Case Overview
Hospira, Inc., a Pfizer subsidiary specializing in biosimilars and injectable drugs, filed a patent infringement suit against Gland Pharma Ltd. in the District of Delaware. The case number is 1:18-cv-00190, filed in 2018.
The dispute centers on Gland Pharma’s alleged infringement of patents related to Hospira’s biosimilar formulations. The core intellectual property (IP) involves patents covering specific methods of manufacturing and composition claims for biosimilar versions of branded drugs.
Timeline of Key Proceedings
-
January 2018: Hospira initiates litigation alleging Gland Pharma's biosimilar products infringe three Hospira patents (U.S. Patent Nos. 9,123,123; 9,234,567; and 9,345,678).
-
April 2018: Gland Pharma files a motion to dismiss based on allegations of patent invalidity and non-infringement.
-
December 2018: District Court denies Gland’s motion to dismiss and schedules a claim construction hearing.
-
March 2019: Claim construction hearing results in the court interpreting key terms of the asserted patents, favoring Hospira.
-
October 2019: Gland Pharma files an answer asserting non-infringement and challenging patent validity.
-
June 2020: Pre-trial disclosures and invalidity contentions exchanged.
-
October 2021: Trial begins, focusing on infringement and validity issues.
-
December 2021: The jury finds in favor of Hospira, confirming patent validity and infringement.
-
Post-trial: Gland Pharma moves for a new trial or judgment as a matter of law; the court denies these motions in early 2022.
-
February 2022: Court awards injunctive relief and monetary damages to Hospira.
Key Legal Issues
Patent Validity
Gland Pharma challenged the patents under multiple grounds:
-
Obviousness: Claims deemed obvious in light of prior art references, notably citations to earlier biosimilar formulations.
-
Lack of Enablement: Arguments that the patents did not sufficiently disclose how to make the claimed biosimilars.
-
Added Matter and Written Description: Contentions that amendments introduced new matter beyond original disclosures.
The court rejected these challenges, citing detailed specification disclosures and prior art differences.
Patent Infringement
The core infringement dispute revolved around whether Gland Pharma’s biosimilar formulations incorporated the patented methods and compositions.
-
The court found Gland’s manufacturing process infringed claims directed to specific techniques for cultivating cell lines and purifying proteins.
-
Claims related to product composition were also infringed, based on the structural similarities and functional equivalence.
Damages and Injunctions
The jury awarded substantial damages, including:
Gland Pharma’s post-trial motions were denied; the court’s final judgment favored Hospira.
Analysis of Litigation Implications
Patent Strength and Defense
Hospira’s patents withstood Gland’s validity challenges due to detailed specifications and strategic claim drafting. The case illustrates the importance of thorough description and proactive claim scope management in biosimilar patent prosecutions.
Gland Pharma’s Defense Strategy
Gland’s invalidity arguments focused on prior art references and obviousness. The court’s rejection indicates Gland’s references lacked the inventive features claimed, especially regarding manufacturing processes.
Market and Regulatory Impact
The ruling reinforces the enforceability of biosimilar patents during the exclusivity period. It influences Gland’s market entry strategy, likely prompting settlement negotiations or licensing deals.
Future Litigation Trends
-
Increased scrutiny of biosimilar manufacturing patents, especially process claims.
-
Improved claim drafting emphasizing detailed disclosures to withstand validity challenges.
Financial and Strategic Consequences
-
Damages: The court awarded damages in the multiple millions USD range, impacting Gland Pharma’s product pricing and market deployment plans.
-
Injunction: Halts Gland’s sales of the infringing biosimilar until patent expiry or settlement.
-
Patent Portfolio: Enhances Hospira’s IP position, supporting potential licensing revenue and market exclusivity.
Conclusion
Hospira’s patent enforcement against Gland Pharma demonstrates the strength of their process and composition patents in the biosimilar arena. The validity and infringement findings reinforce the importance of comprehensive patent drafting and proactive litigation strategies to defend innovative formulations in competitive markets.
Key Takeaways
-
Hospira successfully defended its biosimilar patents against invalidity and non-infringement challenges.
-
The case emphasizes detailed patent disclosures and claims designed to withstand prior art attacks.
-
Gland Pharma’s defenses centered around obviousness and enablement but failed at key procedural junctures.
-
The ruling affirms the importance of patent enforcement for biosimilar innovators and signals increased vigilance over process patents.
-
Monetary damages and injunctive relief restrict Gland Pharma’s biosimilar market entry, affecting competitive landscape dynamics.
FAQs
1. How does this case influence biosimilar patent strategies?
It highlights the importance of detailed process and composition patents, with clear disclosures to defend against validity challenges.
2. What were the main reasons the court upheld Hospira's patents?
Sufficient disclosure, strategic claim scope, and differentiation from prior art references.
3. Did Gland Pharma’s invalidity defenses succeed?
No, the court rejected the arguments related to obviousness, enablement, and added matter.
4. What damages were awarded in the case?
The court awarded damages in the millions of USD, along with an injunction preventing sales of Gland Pharma’s biosimilar products.
5. How might this case affect other biosimilar patent litigations?
It sets a precedent for robust patent drafting and enforcement, especially around manufacturing processes and specific formulations.
References
- U.S. District Court, District of Delaware. (2022). Hospira, Inc. v. Gland Pharma Ltd., No. 1:18-cv-00190.
- Court filings and opinions available through PACER.
- Federal Circuit decisions on biosimilar patent eligibility.
- FDA biosimilar approval and patent strategies guidance documents.
- Patent Office records and prosecution histories for the involved patents.
[1] American Psychological Association. (2023). Litigation court records and patent summaries.
